Yoshitake Yokokura, president of the Japan Medical Association (JMA), on May 15 favorably received the 33.5 million yen NHI price given to Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel), saying it is about two-thirds of its US price. Speaking to…
To read the full story
Related Article
ORGANIZATION
- JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
November 11, 2025
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
- MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
October 22, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…





